The economic and humanistic burden of patients in receipt of current available therapies for nAMD
Abstract
Aim: To determine the economic and humanistic burden of neovascular age-related macular degeneration (nAMD) in a cohort of patients treated with anti-VEGF in Europe and the US. Patients & methods: 79 respondents from the EU and 63 from the US with a self-reported diagnosis of nAMD and in current receipt of treatment, as reported in an international, general population survey, were compared with non-nAMD controls. Results: Anti-VEGF-treated nAMD patients in the EU had a greater utilization of healthcare resources, poorer quality of life and greater overall activity impairment versus non-nAMD controls. In the US cohort, treated nAMD patients had significantly greater resource utilization for ophthalmologist visits only. Conclusion: The burden of care associated with nAMD on EU and US healthcare systems, and on patients who are in receipt of nAMD therapy, is significant and likely to be unsustainable.
Formats available
You can view the full content in the following formats:
References
1.
Wong WL, Su X, Li X et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health. 2(2), e106–e116 (2014).
2.
Friedman DS, O'Colmain BJ, Munoz B et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122(4), 564–572 (2004).
3.
Colijn JM, Buitendijk GHS, Prokofyeva E et al. Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology 124(12), 1753–1763 (2017).
4.
Brown DM, Michels M, Kaiser PK et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1), 57–65.e5 (2009).
5.
Ho AC, Busbee BG, Regillo CD et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121(11), 2181–2192 (2014).
6.
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121(1), 193–201 (2014).
7.
Peden MC, Suner IJ, Hammer ME et al. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology 122(4), 803–808 (2015).
8.
Razi F, Haq A, Tonne P et al. Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes. Clin. Ophthalmol. 10, 313–319 (2016).
9.
Bressler NM, Doan QV, Varma R et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch. Ophthalmol. 129(6), 709–717 (2011).
10.
Brown MM, Brown GC, Stein JD et al. Age-related macular degeneration: economic burden and value-based medicine analysis. Can. J. Ophthalmol. 40(3), 277–287 (2005).
11.
Dawson SR, Mallen CD, Gouldstone MB et al. The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data. BMC Ophthalmol. 14, 78 (2014).
12.
Bandello F, Lafuma A, Berdeaux G. Public health impact of neovascular age-related macular degeneration treatments extrapolated from visual acuity. Invest. Ophthalmol. Vis. Sci. 48(1), 96–103 (2007).
13.
Dong LM, Childs AL, Mangione CM et al. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Am. J. Ophthalmol. 138(1), 91–108 (2004).
14.
Huo T, Guo Y, Shenkman E et al. Assessing the reliability of the short form 12 (SF-12) health survey in adults with mental health conditions: a report from the wellness incentive and navigation (WIN) study. Health Qual. Life Outcomes 16(1), 34 (2018).
15.
Zhang W, Bansback N, Boonen A et al. Validity of the work productivity and activity impairment questionnaire – general health version in patients with rheumatoid arthritis. Arthritis Res. Ther. 12(5), R177 (2010).
16.
Chaudhry S, Jin L, Meltzer D. Use of a self-report-generated Charlson Comorbidity Index for predicting mortality. Med. Care 43(6), 607–615 (2005).
17.
Ruiz-Moreno JM, Coco RM, Garcia-Arumi J et al. Burden of illness of bilateral neovascular age-related macular degeneration in Spain. Curr. Med. Res. Opin. 24(7), 2103–2111 (2008).
18.
Sahel JA, Bandello F, Augustin A et al. Health-related quality of life and utility in patients with age-related macular degeneration. Arch. Ophthalmol. 125(7), 945–951 (2007).
19.
Mehta H, Tufail A, Daien V et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog. Retin. Eye Res. 65, 127–146 (2018).
Information & Authors
Information
Published In
Copyright
© 2018 Jaffe, Chan, Bezlyak, Skelly.
History
Received: 22 June 2018
Accepted: 3 August 2018
Published online: 21 September 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
The economic and humanistic burden of patients in receipt of current available therapies for nAMD. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0058
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Qianyi Deng, Kazumasa Kishimoto, Osamu Sugiyama, Masahiro Miyake, Hiroshi Tamura, Automatic selection of optical coherence tomography images for prognostic prediction models in age-related macular degeneration, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2026.109384, 282, (109384), (2026).
- Billal Hossain, Sabrina Rahmatullah, Tanvir Ahmed, Efficacy of brolucizumab and ranibizumab in diabetic macular edema and neovascular age-related macular degeneration: insights from a case series, Annals of Medicine & Surgery, 10.1097/MS9.0000000000003363, (2026).
- Xiuli Chen, Hong Bian, Zhifeng Wu, Validation of the Chinese version of the financial toxicity scale in patients with wet age-related macular degeneration, Journal of Patient-Reported Outcomes, 10.1186/s41687-025-00909-x, 9, 1, (2025).
- Seenu M. Hariprasad, Frank G. Holz, Carl V. Asche, Amine Issa, Oriol Mora, Simon Keady, Mourad F. Rezk, Phil Sarocco, Steven Simoens, Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review, Ophthalmology and Therapy, 10.1007/s40123-025-01104-3, 14, 4, (621-641), (2025).
- Alexander J. E. Foss, David Almeida, Chui Ming Gemmy Cheung, Yuichiro Ogura, Eduard de Cock, Theo Empeslidis, To Treat or Not to Treat? Resolving the Question of Subretinal and Intraretinal Fluid in Age-Related Macular Degeneration: A Narrative Review, Ophthalmology and Therapy, 10.1007/s40123-025-01093-3, 14, 3, (489-514), (2025).
- David T Wong, Shaheer Aboobaker, David Maberley, Sanjay Sharma, Pradeepa Yoganathan, Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations, BMJ Open Ophthalmology, 10.1136/bmjophth-2024-001967, 10, 1, (e001967), (2025).
- Jared S. Nielsen, Andrew Chang, Nancy M. Holekamp, Melina Cavichini-Cordeiro, Stephanie L. Lin, Dominic Heinrich, Katie F. Maass, Alicia Menezes, Natasha Singh, Dante J. Pieramici, Supplemental Intravitreal Ranibizumab Injections in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial, Ophthalmology Retina, 10.1016/j.oret.2024.06.012, 8, 12, (1127-1139), (2024).
- Prem A.H. Nichani, Marko M. Popovic, Andrew Mihalache, Ananya Pathak, Rajeev H. Muni, David T.W. Wong, Peter J. Kertes, Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis, Ophthalmologica, 10.1159/000541662, 247, 5-6, (355-372), (2024).
- Sunil Patel, Philip P. Storey, Mark R. Barakat, Vrinda Hershberger, William Z. Bridges, David A. Eichenbaum, David R. Lally, David S. Boyer, Sophie J. Bakri, Monica Roy, Dario A. Paggiarino, Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration, Ophthalmology Science, 10.1016/j.xops.2024.100527, 4, 5, (100527), (2024).
- Anna-Maria Kubin, Ida Korva-Gurung, Pasi Ohtonen, Nina Hautala, Health-related quality of life in patients with neovascular age-related macular degeneration: a prospective cohort study, Journal of Patient-Reported Outcomes, 10.1186/s41687-024-00775-z, 8, 1, (2024).
- See more